Morgan Stanley Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price

Insmed (NASDAQ:INSM) had its price target increased by Morgan Stanley from $157.00 to $162.00 in a report issued on Friday,Benzinga reports. The firm currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other analysts have also recently issued reports on the stock. The Goldman Sachs Group increased their target price on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Royal Bank Of Canada upped their price target on shares of Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a report on Wednesday, January 21st. Rothschild & Co Redburn assumed coverage on Insmed in a research report on Thursday, December 4th. They issued a “buy” rating and a $263.00 price objective on the stock. Wedbush set a $203.00 target price on Insmed in a research report on Thursday, December 18th. Finally, HC Wainwright decreased their target price on Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research note on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $206.04.

Insmed Trading Down 0.6%

Shares of INSM stock opened at $156.87 on Friday. The company’s fifty day simple moving average is $180.24 and its two-hundred day simple moving average is $158.21. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed has a 1 year low of $60.40 and a 1 year high of $212.75. The stock has a market capitalization of $33.46 billion, a price-to-earnings ratio of -25.34 and a beta of 1.08.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The company had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.Insmed’s revenue was up 52.4% on a year-over-year basis. During the same period in the previous year, the business earned ($1.27) earnings per share. As a group, analysts anticipate that Insmed will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. This trade represents a 5.89% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the sale, the insider directly owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. This represents a 33.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 296,799 shares of company stock worth $54,296,286. Company insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently made changes to their positions in INSM. CoreCap Advisors LLC bought a new position in shares of Insmed during the fourth quarter valued at about $27,000. GraniteShares Advisors LLC purchased a new stake in Insmed during the 4th quarter valued at about $30,000. CIBC Private Wealth Group LLC grew its position in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 53 shares during the last quarter. Stone House Investment Management LLC bought a new position in Insmed during the 3rd quarter worth approximately $29,000. Finally, SBI Securities Co. Ltd. increased its stake in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 166 shares during the period.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.